Chlamydia infection future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
|
Chlamydia infection Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chlamydia infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Chlamydia infection future or investigational therapies |
|
FDA on Chlamydia infection future or investigational therapies |
|
CDC on Chlamydia infection future or investigational therapies |
|
Chlamydia infection future or investigational therapies in the news |
|
Blogs on Chlamydia infection future or investigational therapies |
|
Risk calculators and risk factors for Chlamydia infection future or investigational therapies |
Future or Investigational Therapies
Recent phylogenetic studies have revealed that chlamydia shares a common ancestor with modern plants, and retains unusual plant-like traits (both genetically and physiologically). In particular, the enzyme L,L-diaminopimelate aminotransferase, which is related to lysine production in plants, is also linked with the construction of chlamydia's cell wall. The genetic encoding for the enzymes is remarkably similar in plants and chlamydia, demonstrating a close common ancestry.[1] This unexpected discovery may help scientists develop new treatment avenues: if scientists could find a safe and effective inhibitor of L,L-diaminopimelate aminotransferase, they might have a highly effective and extremely specific new antibiotic against chlamydia.
References
- ↑ McCoy AJ, Adams NE, Hudson AO, Gilvarg C, Leustek T, Maurelli AT (2006). "L,L-diaminopimelate aminotransferase, a trans-kingdom enzyme shared by Chlamydia and plants for synthesis of diaminopimelate/lysine". Proc. Natl. Acad. Sci. U.S.A. 103 (47): 17909–14. doi:10.1073/pnas.0608643103. PMID 17093042.